Acetone semicarbazone (a Schiff base) has been synthesized and characterized. Its antineoplastic activity has been studied against Ehrlich ascites carcinoma (EAC) cells in Swiss albino mice by monitoring parameters like tumor weight, survival time, tumor cell growth inhibition and haematological characteristics. It was found that the compound at dose 2.0 mg/kg/day i.p (intra peritoneal) significantly decreases tumor weight, increases life span and reduces tumor cell growth rate in comparison to those of EAC bearing mice. The compound also alters the depleted haematological parameters like red blood cells (RBC), white blood cells (WBC), haemoglobin (Hb) % and differential counts (i.e. lymphocytes, neutrophils, monocytes) of EAC bearing mice towards normal. The compound enhances the number of macrophages in normal mice. The toxic effects of the compound on the host are not very high and the host recovers gradually towards normal within a few days after treatment. The compound can therefore be considered as a new potent antitumor agent. The efficiency is more or less comparable to that of a standard drug like bleomycin (0.3 mg/kg/day, i.p.).

A schiff base acetone semicarbazone has been synthesized and characterized. Its anticancer activities have been studied against Ehrlich Ascites Carcinoma (EAC) cells in swiss albino mice by monitoring the parameters like tumour cell growth inhibition, tumour weight, survival time, peritoneal cells and haematological parameters. It was found that this compound significantly reduces tumour cell growth rate, decreases tumour weight and increases life span in comparison to those of EAC bearing mice. The test compound restored the depleted haematological parameters of EAC bearing mice towards normal. The compound also enhanced number of macrophages in normal mice. The results obtained were compared with those obtained with the standard drug bleomycin.

No abstract